Saturday 17 October 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.37
0.04
−9.76%
Follow TNYA
Tenaya Therapeutics, Inc. (TNYA) P/E ratio
Tenaya Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| TNYA Tenaya Therapeutics, Inc. | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| RLYB Rallybio Corporation compare | 2.0× |
| VXRT VAXART, INC. compare | 2.8× |
| ICCC ImmuCell Corporation compare | 126× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)